Secret Vaccine Meeting: NIH Locks Doors on Adjuvant Deals
Published Date: 3/19/2025
Notice
Summary
The National Institute of Allergy and Infectious Diseases is holding a closed meeting on April 3-4, 2025, to review secret contract proposals for developing vaccine adjuvants. This affects small businesses competing for government research contracts and keeps sensitive info private. The meeting helps decide who gets funding to boost vaccine innovation, with no public access to protect trade secrets and personal data.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Closed Review Protects Trade Secrets
If you are a small business submitting an SBIR contract proposal for adjuvant development (Solicitation PHS 2025-1, NIH/NIAID 142), the review on April 3-4, 2025 will be closed and your confidential trade secrets and personal data will be kept private under 5 U.S.C. 552b(c)(4) and 552b(c)(6).
SBIR Award Decisions for Vaccine Adjuvants
On April 3-4, 2025, the NIAID Special Emphasis Panel will review and evaluate SBIR contract proposals under Solicitation PHS 2025-1 (NIH/NIAID 142) to decide which small businesses receive contracts for adjuvant development for vaccines.
Meeting Closed — No Public Access
The meeting on April 3-4, 2025 will be closed to the public, with no public access to the contract proposals or discussions, in order to protect trade secrets and personal information.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in